Drug profile · INN
ozenoxacin
XEPI
ozenoxacin (XEPI) is a dna gyrase inhibitor. Route of administration: topical. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — ozenoxacin
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
ozenoxacin (XEPI) is a dna gyrase inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
INN ozenoxacin
Brand XEPI
Mechanism DNA gyrase inhibitor
Target DNA gyrase
Route TOPICAL
Formulation CREAM
Mechanism of action
DNA gyrase inhibitor
Primary target: DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ozenoxacin?
ozenoxacin (XEPI) is a dna gyrase inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for ozenoxacin?
XEPI is a marketed brand name for ozenoxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ozenoxacin?
ozenoxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.